药明合联拟配售最多净筹约13.01亿港元

Core Viewpoint - WuXi AppTec announced a placement agreement with an underwriter to fully underwrite up to 22.277 million shares at a price of HKD 58.85 per share, aiming to raise approximately HKD 1.311 billion in total, with net proceeds of about HKD 1.301 billion [1] Fund Utilization - Approximately 90% of the raised funds will be used to expand the company's service capabilities and production capacity, particularly in the areas of antibody-drug conjugates, active pharmaceutical ingredients, and clinical and commercial production [1] - The remaining approximately 10% of the funds will be allocated for the company's working capital and general corporate purposes [1]